P
PERSONALIS INC
NASDAQ: PSNL (Personalis, Inc.)
Last update: 6 hours ago6.64
0.37 (5.90%)
| Previous Close | 6.27 |
| Open | 6.31 |
| Volume | 724,098 |
| Avg. Volume (3M) | 924,677 |
| Market Cap | 562,361,536 |
| Price / Sales | 2.35 |
| Price / Book | 1.63 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2025 - 3 Mar 2025 |
| Profit Margin | -104.52% |
| Operating Margin (TTM) | -55.94% |
| Diluted EPS (TTM) | -1.73 |
| Quarterly Revenue Growth (YOY) | 40.90% |
| Total Debt/Equity (MRQ) | 27.08% |
| Current Ratio (MRQ) | 4.68 |
| Operating Cash Flow (TTM) | -50.77 M |
| Levered Free Cash Flow (TTM) | -21.16 M |
| Return on Assets (TTM) | -18.78% |
| Return on Equity (TTM) | -57.52% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | Personalis, Inc. | Bullish | Bullish |
AIStockmoo Score
0.8
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 4.0 |
| Average | 0.75 |
|
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 19.30% |
| % Held by Institutions | 53.15% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Aigh Capital Management Llc | 30 Sep 2024 | 3,999,064 |
| Blue Water Life Science Advisors, Lp | 30 Sep 2024 | 1,000,000 |
| Sumitomo Mitsui Trust Group, Inc. | 30 Sep 2024 | 792,608 |
| Nikko Asset Management Americas, Inc. | 30 Sep 2024 | 792,608 |
| Acadian Asset Management Llc | 30 Sep 2024 | 508,140 |
| State Of Michigan Retirement System | 30 Sep 2024 | 493,798 |
| Wellington Shields Capital Management, Llc | 30 Sep 2024 | 432,181 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 11.00 (HC Wainwright & Co., 65.66%) | Buy |
| Median | 9.13 (37.50%) | |
| Low | 7.25 (Needham, 9.19%) | Buy |
| Average | 9.13 (37.50%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 5.75 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 20 Dec 2024 | 11.00 (65.66%) | Buy | 5.75 |
| Needham | 20 Dec 2024 | 7.25 (9.19%) | Buy | 5.75 |
| 07 Nov 2024 | 7.25 (9.19%) | Buy | 4.32 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 19 Dec 2024 | Announcement | Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna |
| 16 Dec 2024 | Announcement | Personalis and Tempus Expand Collaboration to Biopharma |
| 20 Nov 2024 | Announcement | Personalis to Participate at Upcoming Investor Conferences |
| 06 Nov 2024 | Announcement | Personalis Reports Third Quarter 2024 Financial Results |
| 05 Nov 2024 | Announcement | Personalis to Present at the Stifel 2024 Healthcare Conference |
| 23 Oct 2024 | Announcement | Personalis to Announce Third Quarter 2024 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |